Effect of osimertinib in ethnic Chinese with EGFR and T790M mutated NSCLC

Study identifier:D5160R00016

ClinicalTrials.gov identifier:NCT03133234

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An Observational, Retrospective, Real World Study of osimertinib in Ethnic Chinese Patients with Locally advanced/Metastatic T790M Mutation-Positive non-small-cell lung cancer (NSCLC )progressed on previous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Medical condition

T790M positive NSCLC patients

Phase

N/A

Healthy volunteers

No

Study drug

osimertinib

Sex

All

Actual Enrollment

47

Study type

Observational

Age

18 Years +

Date

Study Start Date: 23 May 2017
Primary Completion Date: 13 Sept 2017
Study Completion Date: 13 Sept 2017

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -

Verification:

Verified 01 Nov 2018 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria